Intec Pharma (NASDAQ:NTEC) has been assigned a $15.00 target price by Oppenheimer in a research note issued to investors on Wednesday. The firm presently has a “buy” rating on the biotechnology company’s stock. Oppenheimer’s price objective would indicate a potential upside of 185.71% from the company’s current price.
Other research analysts also recently issued research reports about the company. Zacks Investment Research downgraded Intec Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. Maxim Group increased their target price on Intec Pharma from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Monday, March 26th. HC Wainwright started coverage on Intec Pharma in a report on Monday, February 26th. They set a “buy” rating on the stock. Finally, Ladenburg Thalmann started coverage on Intec Pharma in a report on Wednesday, February 28th. They set a “buy” rating on the stock. Two investment analysts have rated the stock with a sell rating and six have issued a buy rating to the company’s stock. Intec Pharma presently has a consensus rating of “Buy” and an average price target of $12.67.
Shares of NTEC opened at $5.25 on Wednesday. The stock has a market capitalization of $166.88, a P/E ratio of -3.18 and a beta of 1.26. Intec Pharma has a one year low of $4.80 and a one year high of $9.80.
Intec Pharma (NASDAQ:NTEC) last issued its quarterly earnings results on Friday, March 9th. The biotechnology company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). equities analysts forecast that Intec Pharma will post -1.15 EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in NTEC. Deutsche Bank AG lifted its holdings in Intec Pharma by 59.2% during the 4th quarter. Deutsche Bank AG now owns 115,217 shares of the biotechnology company’s stock worth $593,000 after buying an additional 42,867 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Intec Pharma by 66.0% during the 4th quarter. Renaissance Technologies LLC now owns 133,500 shares of the biotechnology company’s stock worth $688,000 after buying an additional 53,100 shares during the last quarter. Pura Vida Investments LLC bought a new position in Intec Pharma during the 3rd quarter worth approximately $895,000. Millennium Management LLC bought a new position in Intec Pharma during the 4th quarter worth approximately $1,392,000. Finally, Meitav Dash Investments Ltd. acquired a new stake in shares of Intec Pharma during the 4th quarter worth approximately $8,607,000. 41.39% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at www.tickerreport.com/banking-finance/3350616/intec-pharma-ntec-pt-set-at-15-00-by-oppenheimer.html.
Intec Pharma Company Profile
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
NTEC)' title='Analyst Recommendations for Intec Pharma (NASDAQ:NTEC)' />